Revolution (RVMD) Q1 2026 Earnings Transcript Summary
Revolution Pharmaceuticals (RVMD) reported positive results from its Phase 3 trial for Diraxonrasib in treating metastatic pancreatic cancer, showing a 60% reduction in risk of death compared to chemotherapy. The drug met both primary and secondary endpoints and demonstrated a favorable safety profile. The company plans to submit a New Drug Application to the FDA under the National Priority Voucher Program.
Tickers: $RVMD
Topics: cancer treatment clinical trials drug development FDA pharmaceuticals